In a filing, Passage Bio Inc revealed its Stockholder OrbiMed Private Investments VI acquired Company’s shares for reported $0.11 million on Jul 07 ’25. In the deal valued at $0.43 per share,259,000 shares were bought.
Then, ORBIMED ADVISORS LLC sold 231,600 shares, generating $81,060 in total proceeds. Upon selling the shares at $0.35, the 10% Owner now owns 6,418,400 shares.
Before that, ORBIMED ADVISORS LLC sold 213,257 shares. Passage Bio Inc shares valued at $70,375 were divested by the 10% Owner at a price of $0.33 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 6,066,343 shares, worth roughly $2.49 million.
A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. JP Morgan also remained covering PASG and has decreased its forecast on March 08, 2022 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on January 19, 2022. It rated PASG as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PASG
On Tuesday, Passage Bio Inc [NASDAQ:PASG] saw its stock fall -6.24% to $0.41. Over the last five days, the stock has gained 1.42%. Passage Bio Inc shares have fallen nearly -54.47% since the year began. Nevertheless, the stocks have fallen -28.41% over the past one year. While a 52-week high of $1.33 was reached on 01/02/25, a 52-week low of $0.26 was recorded on 05/14/25.
Levels Of Support And Resistance For PASG Stock
The 24-hour chart illustrates a support level at 0.3858, which if violated will result in even more drops to 0.3657. On the upside, there is a resistance level at 0.4403. A further resistance level may holdings at 0.4747.
How much short interest is there in Passage Bio Inc?
A steep rise in short interest was recorded in Passage Bio Inc stocks on 2025-06-13, growing by 45484.0 shares to a total of 1.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 1.74 million shares. There was a rise of 2.55%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 01, 2021 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
